Home Cart Sign in  
Chemical Structure| 72432-03-2 Chemical Structure| 72432-03-2

Structure of Miglitol
CAS No.: 72432-03-2

Chemical Structure| 72432-03-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Miglitol is a desoxynojirimycin-derived inhibitor of alpha-glucosidase with antihyperglycemic activity.

Synonyms: BAY1099; BAY-m1099; Seibule

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Miglitol

CAS No. :72432-03-2
Formula : C8H17NO5
M.W : 207.22
SMILES Code : O[C@@H]1[C@@H](CO)N(CCO)C[C@H](O)[C@H]1O
Synonyms :
BAY1099; BAY-m1099; Seibule
MDL No. :MFCD28142869
InChI Key :IBAQFPQHRJAVAV-ULAWRXDQSA-N
Pubchem ID :441314

Safety of Miglitol

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01697592 - Completed - -
NCT03492580 - Completed - United States, New Jersey ... More >> Janssen Investigative Site Titusville, New Jersey, United States, 08560 Less <<
NCT02456428 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT02476760 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT02669693 Diabetes Not Applicable Completed - United Kingdom ... More >> School of Food Science and Nutrition, University of Leeds Leeds, West Yorkshire, United Kingdom, LS2 9JT Less <<
NCT02475499 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT01697592 Type 2 Diabetes Mellitus Phase 3 Completed - -
NCT00334399 Type 2 Diabetes Mellitus PHASE3 COMPLETED - Aichi, Japan|Chiba, Japan|Fuku... More >>oka, Japan|Gifu, Japan|Gunma, Japan|Hokkaido, Japan|Ibaragi, Japan|Kanagawa, Japan|Kumamoto, Japan|Miyazaki, Japan|Osaka, Japan|Saitama, Japan|Tochigi, Japan Less <<
NCT01242202 Type 2 Diabetes Mellitus Phase 3 Completed - Japan ... More >> Chubu, Japan Hokkaido, Japan Kansai, Japan Kantou, Japan Kyushu, Japan Touhoku, Japan Less <<
NCT00213070 Type 2 Diabetes Mellitus PHASE3 COMPLETED - Aichi, Japan|Chiba, Japan|Fuku... More >>oka, Japan|Gifu, Japan|Gunma, Japan|Hokkaido, Japan|Ibaraki, Japan|Kagoshima, Japan|Kanagawa, Japan|Kumamoto, Japan|Miyazaki, Japan|Oita, Japan|Okinawa, Japan|Saitama, Japan|Shiga, Japan|Tokyo, Japan Less <<
NCT00213109 Type 1 Diabetes Mellitus PHASE3 COMPLETED - Chiba, Japan|Fukuoka, Japan|Gi... More >>fu, Japan|Ibaraki, Japan|Kanagawa, Japan|Kumamoto, Japan|Oita, Japan Less <<
NCT00334503 Type 2 Diabetes Mellitus PHASE3 COMPLETED - Aichi, Japan|Chiba, Japan|Fuku... More >>oka, Japan|Gunma, Japan|Hokkaido, Japan|Ibaragi, Japan|Kagoshima, Japan|Kanagawa, Japan|Kumamoto, Japan|Miyazaki, Japan|Oita, Japan|Osaka, Japan|Saitama, Japan Less <<
NCT00213122 Type 2 Diabetes Mellitus Phase 3 Completed - Japan ... More >> Ibaraki, Japan Less <<
NCT01099839 Healthy Volunteers ... More >> Pharmacokinetics of ASP1941 Less << Phase 1 Completed - Japan ... More >> Kantou, Japan Less <<
NCT00380822 Type 2 Diabetes Mellitus Phase 3 Completed - Japan ... More >> Aichi, Japan Chiba, Japan Fukuoka, Japan Gunma, Japan Hiroshima, Japan Hyogo, Japan Ibaragi, Japan Ishikawa, Japan Iwate, Japan Kumamoto, Japan Kyoto, Japan Mie, Japan Miyagi, Japan Nagasaki, Japan Niigata, Japan Oita, Japan Okayama, Japan Osaka, Japan Saga, Japan Saitama, Japan Shiga, Japan Shimane, Japan Shizuoka, Japan Tokyo, Japan Toyama, Japan Yamagata, Japan Yamaguchi, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.83mL

0.97mL

0.48mL

24.13mL

4.83mL

2.41mL

48.26mL

9.65mL

4.83mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

[1]Hirose S, Iwahashi Y, et al. Concurrent Therapy with a Low-carbohydrate Diet and Miglitol Remarkably Improved the Postprandial Blood Glucose and Insulin Levels in a Patient with Reactive Hypoglycemia due to Late Dumping Syndrome. Intern Med. 2016;55(9):1137-42.

[2]Joubert PH, Foukaridis GN, Bopape ML. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase. Eur J Clin Pharmacol. 1987;31(6):723-4.

[3]LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Miglitol. 2021 Jan 12

[4]Hirata A, Igarashi M, Iwai H, Tominaga M. Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats. Horm Metab Res. 2009 Mar;41(3):213-20

[5]Komatsu M, Tanaka N, Kimura T, Fujimori N, Sano K, Horiuchi A, Sugiura A, Yamazaki T, Shibata S, Joshita S, Umemura T, Matsumoto A, Tanaka E. Miglitol attenuates non-alcoholic steatohepatitis in diabetic patients. Hepatol Res. 2018 Dec;48(13):1092-1098

[6]Hamada Y, Goto M, Nishimura G, Nagasaki H, Seino Y, Kamiya H, Nakamura J. The alpha-glucosidase inhibitor miglitol increases hepatic CYP7A1 activity in association with altered short-chain fatty acid production in the gut of obese diabetic mice. Metabol Open. 2020 Jan 11;5:100024

[7]Sasaki T, Shimpuku M, Kitazumi T, Hiraga H, Nakagawa Y, Shibata H, Okamatsu-Ogura Y, Kikuchi O, Kim HJ, Fujita Y, Maruyama J, Susanti VY, Yokota-Hashimoto H, Kobayashi M, Saito M, Kitamura T. Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates. Endocr J. 2013;60(10):1117-29

[8]Sasaki T, Hiraga H, Yokota-Hashimoto H, Kitamura T. Miglitol protects against age-dependent weight gain in mice: A potential role of increased UCP1 content in brown adipose tissue. Endocr J. 2015;62(5):469-73

 

Historical Records

Categories